Contact
Please use this form to send email to PR contact of this press release:
Human medicines European public assessment report (EPAR): Tremelimumab AstraZeneca, tremelimumab, Carcinoma, Non-Small-Cell Lung, Date of authorisation: 20/02/2023, Revision: 1, Status: Authorised
TO: